| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |